A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines DNA.HTI and MVA.HTI in Early Treated HIV-1 Positive Individuals
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2017
At a glance
- Drugs HTI immunogen (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms AELIX-002
- Sponsors Aelix Therapeutics
- 05 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Jul 2017 Status changed from not yet recruiting to recruiting.
- 06 Jul 2017 New trial record